Hofseth Biocare ASA: Commences the project for a second hydrolysis plant in Norway to triple capacity
05 Dezembro 2024 - 5:00AM
UK Regulatory
Hofseth Biocare ASA: Commences the project for a second hydrolysis
plant in Norway to triple capacity
Hofseth BioCare ASA ("HBC" or the "Company", and together with
its consolidated subsidiaries, the "Group") is pleased to announce
a Board resolution to start a project to build a second hydrolysis
plant in Berkåk, Norway through HBC Berkåk AS ("HBC Berkåk"), a
wholly owned subsidiary of the Company.
HBC Berkåk will be engaged within the manufacturing, marketing
and sale of clinically proven, human grade, sustainable marine
proteins, collagens, and oils from Norwegian Atlantic salmon
harvested from sustainable aquaculture. The planned capacity of the
Berkåk plant will be 2.5x the current capacity of the Company’s
Midsund facility.
The project will strengthen HBC’s commitment to R&D and
discovery science which has enabled the development of a unique
portfolio of sustainably sourced and clinically proven ingredients
for human and pet markets globally
The Company will over the coming few months aim to secure the
funding for Capex requirements for the Group's Berkåk facility, as
well as other working capital needs for the HBC Berkåk build-out
via bank and leasing facilities. The intention is to develop a
second enzymatic hydrolysis plant to more than triple current
production volumes of HBC’s unique marine ingredients.
Sustainability aspects are firmly integrated into all aspects of
how HBC operates. HBC ensures there is no food waste by using
its proprietary technology and IP to upcycle the raw material
offcuts from the fresh fish not used in the production of fillets
and portions from Norwegian processors, into bioactive ingredients
with patented health benefits and health claims.
The demand for our marine-based proteins continues to grow
strongly, particularly following new published research
demonstrating GLP-1 activation from ProGo® Bioactive Peptides.
For further information, please contact:
Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health ingredient supplier
and an incubator for new pharmaceutical drug leads. For OmeGo®,
clinical trial work with our salmon oil is ongoing to improve lung
health in allergic asthma and urban populations with exposure to
raised pollution levels. A study in mild COVID has completed
successfully demonstrating important immune health benefits for
faster recovery. For CalGo®, preclinical and clinical trial work is
delineating the joint health benefits of the natural, undenatured
type II collagen contained in it. ProGo® provides both metabolic
and gastrointestinal (GI) health benefits. The former includes GLP1
activity and hence consistent weight loss with improved energy
levels from improved iron metabolism. The peptides also support
muscle health providing a triad of benefits important for healthy
ageing and active lifestyles. In terms of GI health, a special
formula of soluble protein hydrolysate (SPH / ProGo®) is being
developed as a Medical Food to help treat Inflammatory Bowel
Disease, and for Iron Deficiency Anemia. Research is ongoing to
identify the individual elements within its ingredients that
modulate inflammation and the immune response with pre-clinical
studies ongoing in multiple clinics and University research
labs.
The company is founded on the core values of sustainability,
optimal utilization of natural resources and full traceability.
Through an innovative hydrolysis technology, HBC can preserve the
quality of the lipids, proteins and calcium from fresh salmon
off-cuts. HBC's headquarters are in Ålesund, Norway with branches
in Oslo, London, Zürich, New Jersey and Palo Alto. HBC is listed on
Oslo Børs with ticker "HBC".
This information is subject to the disclosure requirements
pursuant to Section 5-12 of the Norwegian Securities Trading
Act
Hofseth Biocare Asa (LSE:0Q6H)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Hofseth Biocare Asa (LSE:0Q6H)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024